Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? - Modern Pathology
Roche launches CE-marked VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value | British Journal of Cancer
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
Ventana MMR IHC Panel DECISION SUMMARY A. De Novo Number: DEN170030 B. Purpose for Submission: De novo request for evaluation of
Colorectal IHC portfolio
MMR RxDx Panel | Sonic Healthcare USA Anatomical Pathology
VENTANA MMR RxDx IHC Panel
VENTANA MMR RxDx Panel (CE IVD)
Roche Diagnostics USA on X: "Roche Diagnostics has received FDA approval for VENTANA MMR RxDx Panel to identify solid tumor patients eligible for JEMPERLI (dostarlimab-gxly) treatment. Learn more: https://t.co/enf2OnDbWw #roche #mmrrxdx #targetedtherapy
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
Roche Diagnostics USA on X: "It's time again for #TweetorialTuesday! This month we are focused on the VENTANA MMR IHC Colorectal Carcinoma Panel (VENTANA MMR IHC CRC Panel) #IHCPath #colorectalcarcinoma #mismatchrepair #chromosomalinstability #
JMP | Free Full-Text | DNA Mismatch Repair Proteins and BRAF V600E Detection by Immunohistochemistry in Colorectal Cancer Demonstrates Concordance with Next Generation Sequencing
VENTANA MMR RxDx Panel (US FDA Approved)
Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next‐generation sequencing - Amemiya - 2022 - Cancer Medicine - Wiley Online Library
VENTANA MMR RxDx IHC Panel
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
DNA Mismatch Repair Proteins and BRAF V600E Detection by Immunohistochemistry in Colorectal Cancer Demonstrates Concordance with
FDA Approves VENTANA MMR RxDx Panel | Clinical Lab Products
Roche Receives FDA Approval for VENTANA MMR RxDx Panel to Identify dMMR Solid Tumour Patients and pMMR Endometrial Cancer Patients Eligible for KEYTRUDA - Medtech Alert
Colorectal Cancer Immunohistochemistry Panel Launched - Immunology - mobile.Labmedica.com
VENTANA MMR RxDx Panel (US FDA Approved)
Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? - Modern Pathology
US FDA approves Roche's Ventana panel to identify solid tumour patients